1215074-41-1

Basic information

• Product Name: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine
• Synonyms: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine
• CAS NO: 1215074-41-1
• Molecular Formula: C₇H₂BrCl₂N₃
• Molecular Weight: 278.93
• Mol File: 1215074-41-1.mol

Chemical Properties

• Boiling Point: 323.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.946±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.17±0.30(Predicted)
• CAS DataBase Reference: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine(1215074-41-1)
• EPA Substance Registry System: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine(1215074-41-1)

Safety Data

• Hazardous Substances Data: 1215074-41-1(Hazardous Substances Data)

Upstream product

• 1215074-37-5 7-bromopyrido[3,2-d]pyrimidine-2,4-diol 
• 1334405-60-5 ethyl 3-amino-5-bromopyridine-2-carboxylate 
• 1215074-37-5 7-bromo-1H-pyrido[3,2-d]pyrimidine-2,4-dione 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 669066-89-1 3-amino-5-bromopyridine-2-carboxylic acid amide 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 

Downstream Products

• 1374203-79-8 N,N-dimethyl-4-{3-[4-(4-morpholin-4-yl-7-pyrimidin-5-yl-pyrido[3,2-d]-pyrimidin-2-yl)-phenyl]-ureido}-benzamide 
• 1557084-70-4 C₂₉H₂₉Cl₃N₈O₅ 

Relevant articles and documents

PYRIDOPYRIMIDINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

2-aminopyrimidine compound as well as pharmaceutical composition and application thereof

The invention relates to a 2-aminopyrimidine compound as well as a pharmaceutical composition and application thereof. Specifically, the compound disclosed by the invention has a structure shown as aformula I in the specification, and all the groups and substituents in the formula I are as defined in the specification. The invention further discloses application of the compound in the fields of virus resistance, infection resistance, autoimmunity, tumors and other diseases.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

Substituted Amino-Pyrimidine Derivatives

The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787

In this work we describe the optimization of a lead compound based on the quinazoline template to give a new series of potent pyrido[3,2-d]pyrimidines as histamine H4 receptor antagonists. The pyrido[3,2-d]pyrimidine ligands have significantly reduced hERG binding compared to clinical stage compound PF-3893787 while showing good affinities at the human and rodent histamine receptors. The receptor residence time of several of these new compounds was determined for the human H4R and compared with JNJ7777120 and PF-3893787. The pyrido[3,2-d]pyrimidines showed residence times lower than JNJ7777120 but comparable to the residence time of PF-3893787. Overall, the pyrido[3,2-d]pyrimidines show an excellent in vitro profile that warrants their further investigation in relevant models of human disease.

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.